Cryo-Cell International (NYSEAMERICAN:CCEL) Stock Price Passes Below 200 Day Moving Average – What’s Next?

Posted by ABMN Staff on Jul 9th, 2026

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL – Get Free Report)’s stock price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $3.45 and traded as low as $3.43. Cryo-Cell International shares last traded at $3.43, with a volume of 4,183 shares trading hands.

Cryo-Cell International Stock Down 3.9%

The stock has a market cap of $27.65 million, a price-to-earnings ratio of -10.39 and a beta of 0.49. The company has a 50 day simple moving average of $3.52 and a 200 day simple moving average of $3.45.

Cryo-Cell International (NYSEAMERICAN:CCEL – Get Free Report) last posted its quarterly earnings results on Tuesday, April 14th. The company reported $0.01 earnings per share for the quarter. The company had revenue of $7.68 million during the quarter.

Institutional Trading of Cryo-Cell International

A hedge fund recently bought a new position in Cryo-Cell International stock. Susquehanna International Group LLP purchased a new position in shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL – Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned approximately 0.14% of Cryo-Cell International as of its most recent filing with the Securities and Exchange Commission (SEC). 10.44% of the stock is currently owned by institutional investors.

About Cryo-Cell International

(Get Free Report)

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.